hotspot -WSS

hotspot

author：hotspot 2025-10-01 21:37:44 - browse：228

Ula Jurkunas, associate director of the cornea service at Mass Eye and Ear, performs the first CALEC surgery. Courtesy Mass Eye and Ear

The first time Phillip Durst saw the big A on the chart, he could hardly believe it. It was the first in a series of letters to check his vision in his left eye. “They keep flipping the chart and it keeps getting smaller and smaller, and I keep identifying the letters — that was huge,” said Durst. “It’s like a miracle.”

A year earlier, in April 2017, Durst had lost sight from that same eye after it was hit by a caustic water treatment solution in a work accident. The damage was so severe that a standard corneal transplant would not resolve it. But in April 2018, he underwent a new, innovative procedure: An eye stem cell transplant led by Ula Jurkunas, the associate director of the cornea service at Mass Eye and Ear in Boston.

Durst, now 51 years old, is the first of four patients who were included in a Phase 1 trial of Cultivated Autologous Limbal Epithelial Cell (CALEC) transplant, the results of which were published Friday in Science Advances. The procedure allowed him to become a suitable candidate for another surgery, the artificial corneal transplant, while rehabilitating his vision — and his life.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Why Novartis is going to walk from its acquisition of MorphoSys

leisure time

WSS

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Carvykti CAR

AI gets buy

Devoted Health’s losses in Medicare Advantage persist

Top private equity targets in 2023: cardiology, clinical trials, lasers

leisure time

hotspot

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Drug repurposing or repositioning? The language matters

Readout Newsletter: The latest on Moderna, Apellis, and Merck

After affirmative action ruling, medical educators look to 'holistic review'

David Ricks of Eli Lilly: best biopharma CEO of 2023

Apple is now the first public company to be valued at $3 trillion

Surgery pushed Ben Carson to fame

Medicare details structure of new drug price negotiation program

The Biogen Aduhelm mess could happen again

knowledge

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Prime Medicine, Myeloid Therapeutics clash over genome

Cano Health’s bankruptcy is a warning for Medicare Advantage

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

The CDC's new social media misinformation war

Texas Medical Board asked to define abortion emergency exception

entertainment

entertainment

leisure time

hotspot